Autologous stem cell therapy - NeuroGeneration

Drug Profile

Autologous stem cell therapy - NeuroGeneration

Latest Information Update: 18 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NeuroGeneration
  • Class
  • Mechanism of Action Dopaminergic cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Parkinson's disease

Most Recent Events

  • 18 Jan 2016 No recent reports on development identified - Phase-I for Parkinson's disease in USA (Parenteral)
  • 16 Feb 2009 Efficacy data from a phase I trial in Parkinson's disease released by NeuroGeneration
  • 30 Jun 2005 Phase-I for Parkinson's disease in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top